Autopsy report · NCT03165968

Test and Evaluation of Non-Invasive Neuro-Assessment Devices (NINAD): NeuroKinetics, Inc, iPAS

“COVID19 epidemic, and institutional guidelines for halt of recruitment during epidemic”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Suspended: paused, and may or may not restart.
• 150 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Sponsor

Uniformed Services University of the Health Sciences

Sponsor type

US federal agency

Conditions

Healthy

Interventions

Neuro Kinetics, Inc, i-PAS

Participants

150 (planned, not actual)

Sites

2

Countries

United States

Trials that died the same way

• Iron Isomaltoside Compared With Iron Sucrosein Peritoneal Dialysis Patients
  “Difficult patient recruitment due to COVID-19 epidemic” (81% match in meaning)
• Acute Effects of the Prostaglandin (Alprostadil) on Cerebral and Pulmonary Flow
  “Covid 19 and difficulty with recruitment” (81% match in meaning)
• Pathology and Imaging in Kidney Allografts
  “recruitment difficulties due to impact of COVID-19 pandemic” (79% match in meaning)
• Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery
  “COVID-19 challenges to recruitment” (79% match in meaning)
• Sleep, Insulin Sensitivity, and Weight in Adolescents Post-bariatric Surgery
  “COVID-19 pandemic impacted recruitment” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.